Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial

Thomas C. Krivak, MD, shares the positive results from the RUBY trial of pembrolizumab plus chemotherapy followed by maintenance in patients with dMMR advanced endometrial cancer, supporting its approval and use in this population.

Related Content:

Recent Advances in Treating Endometrial and Cervical CancersGynecologic OncologyOncLive Peer Exchange®

STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers

Dr Moore on AEs Associated With ADC Treatment in Gynecologic Cancers

Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice